Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Broadway performers will sing show tunes at a fundraising event aimed at boosting awareness of pulmonary fibrosis.

The internet is full of false claims. Columnist Sam Kirton shares why fact-checking is important, particularly for the rare disease world.

Each new year brings an influx of marketing about resolutions, hopes, and wishes. If you’re like me, your social media feed is flooded with related ad campaigns this month. A new year often sparks ...

Inhibiting the HIF2 protein — fully, hypoxia-inducible factor 2 — was found to ease scarring in a mouse model of lung injury and could be a promising therapeutic strategy for treating idiopathic ...

Rapidly spreading wildfires have taken over the news headlines from the Los Angeles area, as I write this column. Dry weather and the Santa Ana winds joined forces to create an inferno there.

Columnist Sam Kirton says that at his age, and as someone with pulmonary fibrosis, he's had much experience dealing with grief.

Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study ...

Do you make resolutions for the new year? A revealing joke on the subject has been around for years. In it, an entrepreneur opens and stocks a gym on New Year’s Day to support those who’ve made ...